Literature DB >> 7662573

The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use.

M S Lewis-Jones1, A Y Finlay.   

Abstract

Skin disease can cause severe disability and handicap in children. Measurement of the impact of skin disease on the quality of life is required to aid clinical decision-making, for clinical research, for audit of paediatric dermatology services, and for political reasons, to aid arguments for more resources for the care of children with skin disease. Adult measures are inappropriate, as the lives of children differ markedly from those of adults. The purpose of this study was to create and initially validate a simple practical questionnaire for use in children. One hundred and sixty-nine children, aged 3-16 years, attending a paediatric dermatology clinic, wrote down, with the help of their parents, all the ways in which their skin disease affected their lives. One hundred and eleven different aspects were identified; 10 questions were composed to cover these aspects, using a structure similar to the Adult Dermatology Life Quality Index. This draft questionnaire was piloted on two series, totalling 40 children, and minor alterations were made to improve clarity. The Children's Dermatology Life Quality Index (CDLQI) questionnaire (maximum score 30) was then given to a further 233 dermatology paediatric out-patients (CDLQI mean = 5.1, SD = 4.9), 47 normal controls (mean 0.4, 0.7) and 55 control patients attending a general paediatric clinic (mean 0.7, 2.5). The CDLQI scores for eczema (mean = 7.7, 5.6, n = 47), psoriasis (5.4, 5.0, n = 25) and acne (5.7, 4.4, n = 40), were all highly significantly greater than for moles and naevi (2.3, 2.9, n = 29). The highest mean score was that for scabies (mean = 9.5, 10.5, n = 6).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7662573     DOI: 10.1111/j.1365-2133.1995.tb16953.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  157 in total

1.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.

Authors:  A G de Tiedra; J Mercadal; X Badía; J M Mascaró; R Lozano
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

2.  Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.

Authors:  I Lenoir-Wijnkoop; W M C van Aalderen; G Boehm; D Klaassen; A B Sprikkelman; M J C Nuijten
Journal:  Eur J Health Econ       Date:  2010-12-17

Review 3.  Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.

Authors:  Ana-Maria Vranceanu; Vanessa L Merker; Elyse R Park; Scott R Plotkin
Journal:  J Neurooncol       Date:  2015-02-07       Impact factor: 4.130

Review 4.  The economics of topical immunomodulators for the treatment of atopic dermatitis.

Authors:  William Abramovits; Mark Boguniewicz; Amy S Paller; Diane L Whitaker-Worth; Mary M Prendergast; Michael Tokar; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Quality-of-life outcomes and measurement in childhood atopic dermatitis.

Authors:  Sarah L Chamlin; Mary-Margaret Chren
Journal:  Immunol Allergy Clin North Am       Date:  2010-07-01       Impact factor: 3.479

6.  The Cardiff Acne Disability Index (CADI): linguistic and cultural validation in Serbian.

Authors:  Slavenka Jankovic; Jelica Vukicevic; Sanja Djordjevic; Janko Jankovic; Jelena Marinkovic; Mohammad K A Basra
Journal:  Qual Life Res       Date:  2012-02-24       Impact factor: 4.147

Review 7.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

8.  Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Kathryn S Torok; Thomas A Medsger
Journal:  Rheumatology (Oxford)       Date:  2009-12-14       Impact factor: 7.580

9.  The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Suzanne Li; Kathleen M O'Neil; Elena Pope; Gloria C Higgins; Marilynn Punaro; Egla C Rabinovich; Margalit Rosenkranz; Daniel A Kietz; Paul Rosen; Steven J Spalding; Teresa R Hennon; Kathryn S Torok; Elaine Cassidy; Thomas A Medsger
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

10.  Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Authors:  Kathryn S Torok; Katherine Kurzinski; Christina Kelsey; Jonathan Yabes; Kelsey Magee; Abbe N Vallejo; Thomas Medsger; Carol A Feghali-Bostwick
Journal:  Semin Arthritis Rheum       Date:  2015-06-17       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.